ライフサイエンスコーパス: blood type

1 binding proteins with erythrocytes from each blood type.

2 t or specific details regarding a particular blood type.

3 tested pretransfusion to determine the donor blood type.

4 endent markers, mitochondrial sequences, and blood type.

5 All patients were group A(1) blood type.

6 sified according to the candidates' race and blood type.

7 onsecretor) rather than Le(a- b+) (secretor) blood type.

8 ng error affecting priority of candidates by blood type.

9 tential blood substitute for the rare Bombay blood type.

10 nal creatinine greater than 1.5 mg/dL and AB blood type.

11 xicities in individuals with the rare Lan(-) blood type.

12 lood group antigens correlated strongly with blood type.

13 fter adjustment for study center and patient blood type.

14 the alpha-Gal antigen, also correlated with blood type.

15 (6-14, 15-24, 25-29, 30-34, 35-40), age, and blood type.

16 1 (rs45458701) is responsible for the At(a-) blood type.

17 c.589+1G>C) and thus have the Augustine-null blood type.

18 paper-based assay for the detection of human blood type.

19 orovirus infected humans regardless of A/B/O blood type.

20 or and recipient pairs were matched based on blood types.

21 antation (LT) waitlist experiences among ABO blood types.

22 ting current LT allocation may favor certain blood types.

23 ast 10 days would not be possible with other blood types.

24 ess pronounced effect for infants with other blood types.

25 and specific microscale multiplex assay for blood typing.

26 ermatomyositis and some with polymyositis, a blood type 1 interferon-signature correlates with diseas

27 ers with blood group O than those with non-O blood types (10,353 g versus 3,555 g, P < 0.001).

28 AOR, 2.41 [95% CI, 1.24-4.70]); maternal AB blood type (4.9% stillbirths, 3.0% live births) (vs type

29 of transplantation prepolicy was similar by blood type (8-month incidence 81.0% vs 80.5% for blood t

30 cidence of transplantation relative to other blood types (8-month incidences 86.3% vs 92.1%, respecti

31 resulting in 2-way exchanges mainly between blood type A and B recipients and donors.

32 endogenous antibodies that react with human blood type A antigens in neurons.

33 Low Ccr at screening and blood type A are risk factors for IEC-defined CMV diseas

34 r alpha-D-GalNAc end groups and binds to the blood type A determinant GalNAcalpha1, as well as to ter

35 received a left single-lung allograft from a blood type A donor.

36 cardiovascular and pulmonary diseases), with blood type A or AB, and at an early COVID-19 stage (low

37 derived antibodies must be screened for anti-blood type A reactivity to avoid misidentification of vi

38 nsplantation with a blood group O donor to a blood type A recipient is described.

39 Transplantation of blood type A subgroup 2 (A2) livers into non-A recipient

40 Blood type A was also associated with less lung injury r

41 Lastly, we tested whether blood type A was associated with less donor lung injury

42 Apparent VZV neuronal staining and blood type A were strongly associated (by a chi(2) test,

43 tetra+) in the human milk (HM) of women with blood type A, suggesting genetic origins determining the

44 side hydrolase 109 (GH109) that is active on blood type A-antigen, along with a new subfamily of glyc

45 rons of the 30 to 40% of individuals who are blood type A.

46 and recipients for potential recipients with blood types A, B, and AB; and (2) all recipients who hav

47 Of the four main blood types, A, B, AB, and O, only O can be given to any

48 d type (8-month incidence 81.0% vs 80.5% for blood types-A, B, or AB and blood type-O, respectively,

49 ntified a replicable association between ABO blood type A1 and risk of ARDS among the critically ill,

50 iminating the payback system, and allocating blood type A2 and A2B kidneys to blood type B candidates

51 Kidney transplantation from blood type A2/A2B donors to type B recipients (A2->B) ha

52 , we identified a strong association between blood type and COVID-19 diagnosis, as well as a gene-ric

53 The independent contributions of ABO blood type and RBC transfusion to the risks of antepartu

54 ABO blood type and RBC transfusion were found to be independ

55 to assess the association between ABO and Rh blood types and infection, intubation, and death.

56 is approach, proof-of-concept ABO and D (Rh) blood typing and group A subtyping were successfully per

57 ex, blood product characteristics (including blood type), and transport time.

58 alysis showed that after adjusting for MELD, blood type, and diagnosis, patients listed in the latter

59 several noroviruses is linked to human histo-blood type, and its determinant histo-blood group antige

60 d VTE risk factors, such as body mass index, blood type, and markers of inflammation.

61 imes differ substantially by listing status, blood type, and recipient weight.

62 med according to donor blood type, recipient blood type, and transplant center ABOi volume.

63 he need for assist devices, nonidentical ABO blood types, and younger age.

64 CR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2).

65 YPA) and B (GYPB), which determine MN and Ss blood types, are two major receptors that are expressed

66 Using ABO blood typing as a proof-of-concept, we developed i) an i

67 We selected patients who underwent blood typing as potential live kidney donors for recipie

68 The concept of presenting a paper-based blood typing assay in a barcode-like pattern significant

69 Blood typing assay is a critical test to ensure the sero

70 These channels were then used to perform blood typing assays by introducing a blood sample.

71 atient groups, particularly older, diabetic, blood type B and O and shorter pre-listing dialysis time

72 allocating blood type A2 and A2B kidneys to blood type B candidates.

73 re significantly thinner in individuals with blood type B compared to those with other ABO blood grou

74 ells specifically; however, only tissue from blood type B donors, but not type A or O donors, showed

75 Immune tolerance to alpha-Gal in blood type B individuals might reduce the risk to this a

76 Because of a clerical error, a 67-year-old blood type B patient with idiopathic pulmonary fibrosis

77 new policy, candidates with a CPRA>20%, with blood type B, and aged 18-49 years were more likely to u

78 fied donation and transplantation across the blood-type barrier can increase transplants by 10% (PG0.

79 fied donation and transplantation across the blood-type barrier in kidney exchange.

80 dney donation and transplantation across the blood-type barrier in kidney exchange.

81 When compared with LTx candidates with other blood types, blood type O candidates have longer waiting

82 with FVIII half-life in patients with non-O blood type, but no correlation was observed for type O p

83 h donors to patients, not only with extended blood typing, but also by using genetically determined s

84 Predictors were age, sex, blood type, calculated panel-reactive antibodies, donati

85 Blood type can be visually identified from eluting lengt

86 or/recipient cytomegalovirus (CMV) status or blood type, cold ischemic times, or the incidence of out

87 Gender, age, ABO blood-type, cold ischemia, splenectomy and allograft typ

88 ere no clinically significant differences in blood type compatibility, degree of HLA mismatch, number

89 Although blood-type-compatible transplant is a gold standard, typ

90 The SNP rs514659 (tags O blood type) contributed 15.4% of the variance.

91 Extended blood typing decreases alloimmunization in SCD but is no

92 atterns were associated with different histo-blood types, defined by Lewis, secretor, and ABO types.

93 nvestigated, only one pair with the same ABO blood type demonstrated identity at both alleles.

94 bly found at the nonreducing terminus of the blood type-determining A-antigen and as the initial poin

95 ced a barcode-like design into a paper-based blood typing device by integrating with smartphone-based

96 The proposed paper-based blood typing device is rapidly read by smartphones and e

97 etween participants adhering to a particular blood type diet (experimental group) and participants co

98 the evidence to support the effectiveness of blood type diets has not previously been assessed in the

99 ished studies that presented data related to blood type diets were identified and critically appraise

100 tudies that showed the health effects of ABO blood type diets were identified.

101 to validate the purported health benefits of blood type diets.

102 ing question: In humans grouped according to blood type, does adherence to a specific diet improve he

103 revious sternotomy (P = .0003), nonidentical blood type donor (P = .01), recipient non-blood group A

104 antigen expression, creating a risk for Vel blood typing errors and transfusion reactions.

105 d to donor variables including age, sex, ABO blood type, ethnicity, donor type and recipient variable

106 ts were robust to all transplant regions and blood types, except type AB.

107 study examines LT access discrepancies among blood types, focusing on type AB, and seeks equitable st

108 ability model estimated the total number and blood type frequencies of donor-recipient pairs that wou

109 s on erythrocyte membranes uniquely for each blood type, generating differential interactions of the

110 forms to determine the association of the A1 blood type genotype with ARDS risk.

111 del with smoking, current smokers with non-O blood type had an adjusted OR of 2.68 (95% CI, 2.03-3.54

112 Compared with type O, A and B blood types have higher risk of antepartum and postpartu

113 lung allocation score, body mass index, and blood type (hazard ratio, 1.17; 95% confidence interval,

114 th donor acceptance were for male donor sex, blood type, hepatitis C antibody, donor age, left ventri

115 Beyond blood typing, hereditary hemochromatosis-associated HFE

116 e activity measurements and calculated whole-blood type I IFN gene and chemokine scores.

117 eukocytes on day 1, whereas the secretion of blood type I IFNs, which peaked on day 4, did not.

118 Up-regulation of whole blood type I interferon (IFN)-driven transcripts and che

119 e of neurological syndromes; HLA haplotypes; blood type I-IFN signature [RNA quantification of 6 or 2

120 individuals tested for SARS-CoV-2 with known blood type in the New York Presbyterian (NYP) hospital s

121 Incorporating size incompatibility alongside blood type incompatibility further enhances the efficacy

122 r intended recipients due to factors such as blood type incompatibility or size incompatibility.

123 a live donor transplant due to crossmatch or blood type incompatibility.

124 n red blood cells with a rare Augustine-null blood type is associated with macrocytosis, anisopoikilo

125 issued immediately for patients in whom the blood type is known.

126 e updates fitted as time-dependent variable, blood type, listing for malignant disease, and age.

127 e the risk of waiting list death across era, blood types, liver disease diagnosis, and severity (Mode

128 truction of the transplant renal artery with blood type-matched iliac artery grafts should be conside

129 The authors have used preserved, blood type-matched, iliac artery grafts procured from ca

130 Recent evidence suggests blood type may affect risk of severe COVID-19.

131 d to the growing body of evidence suggesting blood type may play a role in COVID-19.

132 109 days) than the 399 candidates with other blood types (median 58 days) (P=0.001).

133 While current blood typing methods are well established, results are s

134 ells (RBCs, erythrocytes) means that careful blood-typing must be carried out prior to transfusion to

135 r African American (23 777 [47.0%]), had ABO blood type O (22 879 [45.2%]), and were Rhesus factor po

136 (27 vs. 25 kg/m2, p = .03), less frequently blood type O (36% vs. 80%, p < .001), and had higher eGF

137 age 29 years), and most were male (90%), and blood type O (79%).

138 Patients with ABO blood type O and B have smaller chances.

139 >3 months after KPD entry included recipient blood type O and calculated panel reactive antibodies >=

140 ction would be different between donors with blood type O and those with non-O.

141 n wait-list mortality; however, infants with blood type O assigned an ABO-I listing strategy were mor

142 the goal of increasing transplant access for blood type O candidates after an error was discovered in

143 with LTx candidates with other blood types, blood type O candidates have longer waiting times and hi

144 with the H-antigen trisaccharide from human blood type O erythrocytes, at 1.67 angstrom resolution.

145 Blood type O is associated with a lower risk of myocardi

146 Blood type O liver transplantation (LT) candidates in th

147 There were more blood type O recipients than blood type O NDDs participating.

148 The 40 blood type O NDDs triggered a mean chain length of 6.0 (

149 Especially highly sensitized and blood type O patients benefit.

150 There were more blood type O recipients than blood type O NDDs participa

151 One hundred thirty-three blood type O recipients were transplanted.

152 and in those with blood type O; The <25 kg, blood type O subgroup experiences longer wait times and

153 n such exchanges to ensure that the standard blood type O wait-list candidates are made better off.

154 orally problematic because it harms standard blood type O wait-list candidates who already have the l

155 s, median wait times were 108 days (<=25 kg, blood type O), 80 days (<=25 kg, non-O), 47 days (>25 kg

156 Compared with blood type O, the ORs for pancreatic cancer in subjects

157 o have a nonischemic cause of heart failure, blood type O, United Network for Organ Sharing status 2

158 lant (n = 90) was greater than the number of blood type O-non-directed donors (n = 32) initiating cha

159 The number of blood type O-patients receiving a transplant (n = 90) wa

160 % CI, 2.03-3.54) compared with nonsmokers of blood type O.

161 241 (96.4%) were White, and 104 (41.6%) had blood type O.

162 isk of myocardial infarction associated with blood type O.

163 hose redemptions were among individuals with blood type O.

164 5 transplants on average, more if the NDD is blood type O.

165 lower in candidates <25 kg and in those with blood type O; The <25 kg, blood type O subgroup experien

166 The incidence rates for blood types O, A, AB, and B were 28.9, 39.9, 41.8, and 4

167 g participants by genotype-derived serologic blood type (O, A, AB, and B).

168 Following CD policy, blood type-O candidates had lower incidence of transplan

169 e impact of initial policy implementation on blood type-O candidates has not been rigorously evaluate

170 Blood type-O candidates were more likely Hispanic and 'O

171 transplants performed prior to CD, 48% were blood type-O recipients compared to 40% post-CD, represe

172 pared to 40% post-CD, representing 138 fewer blood type-O transplants than expected.

173 .0% vs 80.5% for blood types-A, B, or AB and blood type-O, respectively, P = .57).

174 Subsequent blood typing of affected family members confirmed the po

175 t an advance for point of care applications, blood typing of newborns, and general blood assays in sm

176 luated the effects of age, race, gender, and blood type on anti-glycan antibody profiles in the serum

177 sitivity analyses included stratification by blood type or region and potential negative consequences

178 ntered in transfusions of patients with rare blood types or chronically transfused patients who becom

179 or donor RBCs, especially those of universal blood types or free of known and unknown pathogens, has

180 val were seen by donor blood type, recipient blood type, or transplant center ABOi volume.

181 risk of death by era of listing (P = .25) or blood type (P = .31), whereas the risk of death was sign

182 e assist devices (P = .02), nonidentical ABO blood types (P = .05), and younger age (P = .10).

183 ated more African Americans had incompatible blood types (P=0.01) or ineligible recipients (26.7% vs.

184 ted for recipient age, sex, race, ethnicity, blood type, panel reactive antibody, year of placement o

185 nicity, original disease, retransplants, ABO blood type, panel-reactive antibody, previous treatment,

186 ard diet (control group) within a particular blood type population.

187 A blood type rare in one country may not be considered rar

188 recipients were performed according to donor blood type, recipient blood type, and transplant center

189 o differences in survival were seen by donor blood type, recipient blood type, or transplant center A

190 , tumor doubling time, tumor growth pattern, blood type, regional transplant volume, initial tumor si

191 m and current panel reactive antibodies, ABO blood type, retransplants, pretreatment, time on dialysi

192 age, marital status, race and ethnicity, ABO blood type, Rhesus (Rh) factor, and year of delivery.

193 continuous distribution before and after the blood type score modification.

194 Although blood typing showed a very weak expression of Rh antigen

195 Willebrand factor (VWF) protein and purified blood type-specific VWF at arterial shear and measured p

196 This paper presents a microfluidic blood typing system using a small quantity of blood samp

197 to self-manage and need to know if ancillary blood type testing is necessary.

198 ential blood substitutes for the rare Bombay blood type that is characterized by a deficiency of H2 a

199 new, paper-based analytical device (PAD) for blood typing that allows for the simultaneous determinat

200 nded to include the 24,736 patients with any blood type, the results were similar, with rates of deat

201 We estimate Rh-negative blood type to have a protective effect for all three out

202 n LDL-cholesterol responses of different MNS blood types to a low-fat diet.

203 s worldwide but requires careful matching of blood types to avoid serious adverse consequences.

204 itive hematopoiesis may produce many diverse blood types via a common multipotent progenitor, primiti

205 e population attributable fraction for non-O blood type was 19.5%.

206 Rhesus blood type was associated with better survival in HF pat

207 Neither Lewis antigen nor salivary antigen blood type was associated with seroconversion.

208 Rhesus-negative (Rh-) blood type was protective against SARS-CoV-2 infection (

209 ABO and Lewis blood typing was done for 38 women with RVVC (case-patie

210 ender, peak panel-reactive antibody, and ABO blood type were not found to be significant risk factors

211 Advantages with respect to the need for blood typing were balanced with various undesirable prop

212 ith A, B, and O secretors and Lewis positive blood types, were sensitive to the virus, while the non-

213 The exposure measure was ABO blood type, which is not inherently related to outcome,

214 The Augustine-negative alias At(a-) blood type, which seems to be restricted to people of Af

215 subgroup, we determined the associations of blood type with plasma levels of endothelial glycoprotei

216 lf a century ago but remains one of the last blood types with no known genetic basis.